Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the longer-term cost-effectiveness of a nurse-coordinated preventive cardiology programme for primary prevention of cardiovascular disease (CVD) compared to routine practice from a health service perspective. Design: A matched, paired cluster-randomised controlled trial. Setting: Six pairs of general practices in six countries. Participants: 1019 patients were randomised to the EUROACTION intervention programme and 1005 patients to usual care (UC) and who completed the 1-year follow-up. Outcome measures: Evidence on health outcomes and costs was based on patient-level data from the study, which had a 1-year follow-up period. Future risk of CVD events was modelled, using published risk models based on patient characteristics. An individual-level Markov model for each patient was used to extrapolate beyond the end of the trial, which was populated with data from published sources. We used an 11-year time horizon and investigated the impact on the cost-effectiveness of varying the duration of the effect of the intervention beyond the end of the trial. Results are expressed as incremental cost per quality-adjusted life-year gained. Results: Unadjusted results found the intervention to be more costly and also more effective than UC. However, after adjusting for differences in age, gender, country and baseline risk factors, the intervention was dominated by UC, but this analysis was not able to take into account the lifestyle changes in terms of diet and physical activity. Conclusions: Although the EUROACTION study achieved healthier lifestyle changes and improvements in management of blood pressure and lipids for patients at high risk of CVD, compared to UC, it was not possible to show, using available risk equations which do not incorporate diet and physical activity, that the intervention reduced longer-term cardiovascular risk cost-effectively. Whether or not an intervention such as that offered by EUROACTION is cost-effective requires a longer-term trial with major cardiovascular events as the outcome. Trial Registration number: ISRCTN 71715857.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Prevention of CVD, either by lifestyle changes or medication, is costeffective in many scenarios, including population-based approaches and actions directed at high-risk individuals.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [7]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“In general, lifestyle changes may be more cost effective at the population level than drug treatments ( Table 3 ).”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Self-citationRidker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814 · cited 1×
“hs-CRP [16-17] although these models also have their own limitations.”
BackgroundGraham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Self-citationVariations in population health status: results from a United Kingdom national questionnaire survey
Kind, P., Dolan, P., Gudex, C., & Williams, A. (1998) · BMJ · doi:10.1136/bmj.316.7133.736 · Cited by 1,059 · cited 2×
“Sources: Event free (Kind et al, 1998) [13]; Stable angina (Meslop et al, 2003) [24]; Unstable angina and MI (Goodacre et al, 2004) [25]; TIA (Kind et al, 1998) [13]; Stroke (Tengs et al, 2003) [26] Page 29 of 33”
Woodward, M., Brindle, P., & Tunstall-Pedoe, H. (2007) · Heart · doi:10.1136/hrt.2006.108167 · Cited by 667
A systematic review of rapid diagnostic tests for the detection of tuberculosis infection
Dinnes, J., Deeks, J., Kunst, H., Gibson, A., Cummins, E., Waugh, N., Drobniewski, F., & Lalvani, A. (2007) · Health Technology Assessment · doi:10.3310/hta11030 · Cited by 666
Wood, D., Kotseva, K., Connolly, S., Jennings, C., Mead, A., Jones, J., Holden, A., De Bacquer, D., Collier, T., De Backer, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60868-5 · Cited by 601 · cited 3×
“The principal results concluded that the EUROACTION programme achieved healthier lifestyle changes and improvements in risk factor management for patients with coronary heart disease (CHD) and those at high risk of CVD, together with their partners, compared to usual care (UC).(4) While there is evidence that the EURO…”
InfluentialSelf-citationA systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Bamford, J., Sandercock, P., Dennis, M., Warlow, C., Jones, L., McPherson, K., Vessey, M., Fowler, G., Molyneux, A., & Hughes, T. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.11.1373 · Cited by 470
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238 · cited 1×
“manage to achieve these recommended lifestyle and risk factor goals and there remains considerable potential to reduce CVD risk in these patients.(2) The EUROACTION study was designed to address the need for preventive cardiology care in everyday clinical practice.”
Self-citationWarlow, C. P. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301381 · Cited by 211
Incidence of transient ischemic attacks in Oxfordshire, England.
Dennis, M. S., Bamford, J. M., Sandercock, P. A., & Warlow, C. P. (1989) · Stroke · doi:10.1161/01.str.20.3.333 · Cited by 198
Determining Transition Probabilities: Confusion and Suggestions
Miller, D. K., & Homan, S. M. (1994) · Medical Decision Making · doi:10.1177/0272989x9401400107 · Cited by 197
Lifestyle interventions in primary care: systematic review of randomized controlled trials.
Fleming, P., & Godwin, M. S. (2008) · PubMed · Cited by 113
Briggs, A. H., Mihaylova, B., Sculpher, M., Hall, A. S., Wolstenholme, J. L., Simoons, M. L., Deckers, J. W., Ferrari, R., Remme, W. J., Bertrand, M. E., et al. (2006) · Heart · doi:10.1136/hrt.2005.086728 · Cited by 65 · cited 1×
“[11] Transition probabilities for moving from primary event health states to subsequent non-fatal health states are taken from Ward et al.”
Wood, D. A. (2004) · European Heart Journal Supplements · doi:10.1093/eurheartj/6.suppl_j.j3 · Cited by 44
Self-citationIncidence of coronary heart disease in a health authority in London: review of a community register
Sutcliffe, S. J., Fox, K. F., Wood, D. A., Sutcliffe, A., Stock, K. J., Wright, M., Akhras, F., & Langford, E. (2003) · BMJ · doi:10.1136/bmj.326.7379.20 · Cited by 24 · cited 2×
“Transition probabilities We disaggregated the overall risk of a CVD event into rates for specific events by age and gender, using UK relative incidence rates based on published literature [7-9] and expert opinion, as previously used in Ward et al [10].”
MethodSelf-citation
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citation2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.(7,10,11) Cost-effectiveness results strongly depend on parameters such as the target population’s age, the ov…”
BackgroundSelf-citationAuthors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
“Most studies assessing the cost-effectiveness of CVD prevention combine evidence from clinical research with simulation approaches, while cost-effectiveness data from randomized controlled trials (RCTs) are relatively scarce.(15,16) Cost-effectiveness strongly depends on parameters such as the target population’s age,…”
Self-citation
Metadata
- Authors
- Mistry, H., Morris, S., Dyer, M., Kotseva, K., Wood, D., & Buxton, M.
- Affiliations
- Brunel University of London (GB)
- Department of Applied Health Research, University College London, London, UK
- National Institute for Health and Care Excellence (GB)
- Imperial College London (GB)
- Corresponding author
- Mistry, Hema
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 5
- Pages
- e001029
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3488746
- OpenAlex
- W2139786027
- Cited by
- 48
- References
- 21
- Citations by year
- 2024: 2 · 2022: 4 · 2021: 13 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 8 · 2016: 10 · 2013: 3 · 2012: 1
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Brunel University Research Archive (BURA) (Brunel University London) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc)
- Funders
- European Society of Cardiology
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- cost-effectiveness, preventive cardiology, cardiovascular disease prevention, primary care, cardiovascular risk, Markov model, quality-adjusted life years, blood pressure control, lipid control, lifestyle modification, diet and physical activity, risk prediction model
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.